The BioNTech vaccine against the coronavirus works against the mutated strain detected in Britain, but it could also adapt a separate vaccine if necessary in six weeks, said the co-founder of BioNTech on Tuesday. Ugur Sahin, the Co-founder of BioNTech said, "Scientifically, it is highly likely that the immune response by this vaccine also can deal with the new virus variant".
He added, if needed, "in principle the beauty of the messenger technology is that we can directly start to engineer a vaccine which completely mimics this new mutation -- we could be able to provide a new vaccine technically within six weeks". He added the variant detected in Britain has nine mutations, rather than just one as is usually common existing from beginning. Irrespective of any other things, he voiced confidence that the vaccine developed with Pfizer would be efficient because it "contains more than 1,000 amino acids, and only nine of them have changed, so that means 99 percent of the protein is still the same".
He said the company has already started tests on the variant, with results expected in two weeks. "We have scientific confidence that the vaccine might protect but we will only know it if the experiment is done... we will publish the data as soon as possible," he added.
BioNTech to boost vaccine capacity to beat new strain
Pfizer-BioNTech works against new variant too: EU approves the Vaccine
Switzerland to go ahead with Pfizer BioNTech vaccine, Covid 19 vaccination